Top

Published in:

01-07-2018 | Clinical Study

Characteristics of time-activity curves obtained from dynamic ¹¹C-methionine PET in common primary brain tumors

Authors: Yuichi Nomura, Yoshitaka Asano, Jun Shinoda, Hirohito Yano, Yuka Ikegame, Tomohiro Kawasaki, Noriyuki Nakayama, Takashi Maruyama, Yoshihiro Muragaki, Toru Iwama

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

Purpose

The aim of this study was to assess whether dynamic PET with ¹¹C-methionine (MET) (MET-PET) is useful in the diagnosis of brain tumors.

Methods

One hundred sixty patients with brain tumors (139 gliomas, 9 meningiomas, 4 hemangioblastomas and 8 primary central nervous system lymphomas [PCNSL]) underwent dynamic MET-PET with a 3-dimensional acquisition mode, and the maximum tumor MET-standardized uptake value (MET-SUV) was measured consecutively to construct a time-activity curve (TAC). Furthermore, receiver operating characteristic (ROC) curves were generated from the time-to-peak (TTP) and the slope of the curve in the late phase (SLOPE).

Results

The TAC patterns of MET-SUVs (MET-TACs) could be divided into four characteristic types when MET dynamics were analyzed by dividing the MET-TAC into three phases. MET-SUVs were significantly higher in early and late phases in glioblastoma compared to anaplastic astrocytoma, diffuse astrocytoma and the normal frontal cortex (P < 0.05). The SLOPE in the late phase was significantly lower in tumors that included an oligodendroglial component compared to astrocytic tumors (P < 0.001). When we set the cutoff of the SLOPE in the late phase to − 0.04 h⁻¹ for the differentiation of tumors that included an oligodendroglial component from astrocytic tumors, the diagnostic accuracy was 74.2% sensitivity and 64.9% specificity. The area under the ROC curve was 0.731.

Conclusions

The results of this study show that quantification of the MET-TAC for each brain tumor identified by a dynamic MET-PET study could be helpful in the non-invasive discrimination of brain tumor subtypes, in particular gliomas.

Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP (1982) Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32(12):1323–1329CrossRefPubMed

Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM (1995) Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195(1):47–52. https://doi.org/10.1148/radiology.195.1.7892494 CrossRefPubMed

Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, Mineura K, Uemura K (1996) Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. Am J Neuroradiol 17(2):345–353PubMed

Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39(5):778–785PubMed

Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, Mendoza G, Weber-Luxenburger G, Lottgen J, Thiel A, Wienhard K, Heiss WD (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50(5):1316–1322CrossRefPubMed

De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95(5):746–750. https://doi.org/10.3171/jns.2001.95.5.0746 CrossRefPubMed

Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, Senda M, Ishii K, Hirakawa K, Ohno K (2005) Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103(3):498–507. https://doi.org/10.3171/jns.2005.103.3.0498 CrossRefPubMed

Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC (2005) 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32(1):52–59. https://doi.org/10.1007/s00259-004-1598-6 CrossRefPubMed

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougere C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response assessment in neuro-oncology working group and European association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18(9):1199–1208. https://doi.org/10.1093/neuonc/now058 CrossRefPubMedPubMedCentral

10.

Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L (2006) [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. Am J Neuroradiol 27(7):1432–1437PubMed

11.

Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, Maruyama T, Muragaki Y, Iwama T (2008) Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. Am J Neuroradiol 29(10):1867–1871. https://doi.org/10.3174/ajnr.A1242 CrossRefPubMed

12.

Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, Tamiya T (2008) 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35(11):2009–2017. https://doi.org/10.1007/s00259-008-0847-5 CrossRefPubMed

13.

Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K (2008) Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49(5):694–699. https://doi.org/10.2967/jnumed.107.048082 CrossRefPubMed

14.

Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y, Shinoda J, Yano H, Iwama T (2012) Evaluation of brain tumors using dynamic 11C-methionine-PET. J Neurooncol 109(1):115–122. https://doi.org/10.1007/s11060-012-0873-9 CrossRefPubMed

15.

Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, Baum RP (2011) Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 36(10):841–847. https://doi.org/10.1097/RLU.0b013e3182291b40 CrossRefPubMed

16.

Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn JC, Kretzschmar HA, Popperl G, Kreth FW (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 13(3):307–316. https://doi.org/10.1093/neuonc/noq196 CrossRefPubMedPubMedCentral

17.

Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, Lutz J, Egensperger R, Giese A, Herms J, Weller M, Kretzschmar H, Tonn JC, la Fougere C, Kreth FW (2015) Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. Int J Cancer 136(9):2132–2145. https://doi.org/10.1002/ijc.29259 CrossRefPubMed

18.

Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen KJ (2015) The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol 17(9):1293–1300. https://doi.org/10.1093/neuonc/nov088 PubMedPubMedCentralCrossRef

19.

Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, Bauer E, Hamisch C, Ruge MI, Kocher M, Kuchelmeister K, Sellhaus B, Sabel M, Fink GR, Shah NJ, Langen KJ, Galldiks N (2017) Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro Oncol 19(2):281–288. https://doi.org/10.1093/neuonc/now149 PubMedCrossRef

20.

Moulin-Romsee G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, Menten J, Bormans G, Van Laere K (2007) Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging 34(12):2082–2087. https://doi.org/10.1007/s00259-007-0557-4 CrossRefPubMed

21.

Kapouleas I, Alavi A, Alves WM, Gur RE, Weiss DW (1991) Registration of three-dimensional MR and PET images of the human brain without markers. Radiology 181(3):731–739. https://doi.org/10.1148/radiology.181.3.1947089 CrossRefPubMed

22.

Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, Slart RH (2013) Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 40(4):615–635. https://doi.org/10.1007/s00259-012-2295-5 CrossRefPubMed

23.

Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, Popperl G, Kretzschmar HA, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C, Thon N (2012) Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol 14(12):1473–1480. https://doi.org/10.1093/neuonc/nos259 CrossRefPubMedPubMedCentral

24.

Okada Y, Nihashi T, Fujii M, Kato K, Okochi Y, Ando Y, Yamashita M, Maesawa S, Takebayashi S, Wakabayashi T, Naganawa S (2012) Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell Lymphoma using (11)C-methionine and (18)F-FDG PET. Clin Nucl Med 37(9):843–849. https://doi.org/10.1097/RLU.0b013e318262af48 CrossRefPubMed

25.

Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273(37):23629–23632CrossRefPubMed

26.

Nawashiro H, Otani N, Uozumi Y, Ooigawa H, Toyooka T, Suzuki T, Katoh H, Tsuzuki N, Ohnuki A, Shima K, Shinomiya N, Matsuo H, Kanai Y (2005) High expression of L-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathol 22(2):89–91. https://doi.org/10.1007/s10014-005-0188-z CrossRefPubMed

27.

Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T (2010) Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 99(2):217–225. https://doi.org/10.1007/s11060-010-0117-9 CrossRefPubMed

28.

Saito T, Yamasaki F, Kajiwara Y, Abe N, Akiyama Y, Kakuda T, Takeshima Y, Sugiyama K, Okada Y, Kurisu K (2012) Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors. Eur J Radiol 81(8):1863–1869. https://doi.org/10.1016/j.ejrad.2011.04.009 CrossRefPubMed

29.

Zitron IM, Kamson DO, Kiousis S, Juhasz C, Mittal S (2013) In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1. Cancer Biol Ther 14(4):333–339. https://doi.org/10.4161/cbt.23624 CrossRefPubMedPubMedCentral

30.

Shi R, Jiang T, Si L, Li M (2016) Correlations of magnetic resonance, perfusion-weighed imaging parameters and microvessel density in meningioma. J BUON 21(3):709–713PubMed

31.

Liao W, Liu Y, Wang X, Jiang X, Tang B, Fang J, Chen C, Hu Z (2009) Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol 50(2):217–225. https://doi.org/10.1080/02841850802616752 CrossRefPubMed

32.

Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, Neumaier B, Shah NJ, Langen KJ, Galldiks N (2017) Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-017-3846-6 CrossRefPubMed

Title: Characteristics of time-activity curves obtained from dynamic 11C-methionine PET in common primary brain tumors
Authors: Yuichi Nomura
Yoshitaka Asano
Jun Shinoda
Hirohito Yano
Yuka Ikegame
Tomohiro Kawasaki
Noriyuki Nakayama
Takashi Maruyama
Yoshihiro Muragaki
Toru Iwama
Publication date: 01-07-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2834-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Characteristics of time-activity curves obtained from dynamic ¹¹C-methionine PET in common primary brain tumors

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease

ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma

miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma

Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study

JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

Correction to: Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood